Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults
Evidence-based recommendations on brigatinib (Alunbrig) for treating ALK-positive advanced non-small-cell lung cancer in adults who have already had crizotinib
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the
NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults
Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults
Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for differentiated thyroid cancer in adults who have had radioactive iodine
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis (MS) in adults
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults
Evidence-based recommendations on nivolumab (Opdivo) for locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults
Evidence-based recommendations on niraparib (Zejula) for the possible treatment of ovarian, fallopian tube or peritoneal cancer in adults
Evidence-based recommendations on arsenic trioxide (Trisenox)for treating acute promyelocytic leukaemia (APML) in adults
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome (DS) in people aged 2 years and older
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung
Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults
Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a
Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive
Evidence-based recommendations on ribociclib (Kisqali) for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced
Evidence-based recommendations on cemiplimab (Libtayo) for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults
Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia
Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for type 2 diabetes in adults
Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis (RRMS) in adults
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older
NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory CD30-positive Hodgkin lymphoma in adults
Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive, locally recurrent or metastatic (secondary) breast cancer in adults
Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment (with trastuzumab and chemotherapy) of HER2-positive early stage breast cancer
Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer that